Probiotics: insights and new opportunities for Clostridioides difficile intervention

Simple item page
dc.contributor.authorPal, Rushaen
dc.contributor.authorAthamneh, Ahmad I. M.en
dc.contributor.authorDeshpande, Riddhien
dc.contributor.authorRamirez, Jose A. R.en
dc.contributor.authorAdu, Kayode T.en
dc.contributor.authorMuthuirulan, Pushpanathanen
dc.contributor.authorPawar, Shrikanten
dc.contributor.authorBiazzo, Manueleen
dc.contributor.authorApidianakis, Yiorgosen
dc.contributor.authorSundekilde, Ulrik Kraemeren
dc.contributor.authorde la Fuente-Nunez, Cesaren
dc.contributor.authorMartens, Mark G.en
dc.contributor.authorTegos, George P.en
dc.contributor.authorSeleem, Mohamed N.en
dc.date.accessioned2023-11-29T19:42:10Zen
dc.date.available2023-11-29T19:42:10Zen
dc.date.issued2022-05-15en
dc.description.abstractClostridioides difficile infection (CDI) is a life-threatening disease caused by the Gram-positive, opportunistic intestinal pathogen C. difficile. Despite the availability of antimicrobial drugs to treat CDI, such as vancomycin, metronidazole, and fidaxomicin, recurrence of infection remains a significant clinical challenge. The use of live commensal microorganisms, or probiotics, is one of the most investigated non-antibiotic therapeutic options to balance gastrointestinal (GI) microbiota and subsequently tackle dysbiosis. In this review, we will discuss major commensal probiotic strains that have the potential to prevent and/or treat CDI and its recurrence, reassess the efficacy of probiotics supplementation as a CDI intervention, delve into lessons learned from probiotic modulation of the immune system, explore avenues like genome-scale metabolic network reconstructions, genome sequencing, and multi-omics to identify novel strains and understand their functionality, and discuss the current regulatory framework, challenges, and future directions.en
dc.description.versionAccepted versionen
dc.format.extentPages 414-434en
dc.format.extent21 page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1080/1040841X.2022.2072705en
dc.identifier.eissn1549-7828en
dc.identifier.issn1040-841Xen
dc.identifier.issue3en
dc.identifier.orcidSeleem, Mohamed [0000-0003-0939-0458]en
dc.identifier.pmid35574602en
dc.identifier.urihttps://hdl.handle.net/10919/116708en
dc.identifier.volume49en
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pubmed/35574602en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectProbioticsen
dc.subjectC. difficileen
dc.subjectinhibitionen
dc.subjectvirulenceen
dc.subjectimmunomodulatoryen
dc.subjectgenomic explorationen
dc.subjectdiscovery informaticsen
dc.subjectmetabolomicsen
dc.subjectmulti-omicsen
dc.subjectregulatory requirementsen
dc.subject.meshHumansen
dc.subject.meshClostridium Infectionsen
dc.subject.meshVancomycinen
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshProbioticsen
dc.subject.meshClostridioides difficileen
dc.subject.meshClostridioidesen
dc.titleProbiotics: insights and new opportunities for <i>Clostridioides difficile</i> interventionen
dc.title.serialCritical Reviews in Microbiologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherJournalen
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Biomedical Sciences and Pathobiologyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ProbioticsInsights.pdf
Size:
609.33 KB
Format:
Adobe Portable Document Format
Description:
Accepted version
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.5 KB
Format:
Plain Text
Description:
Download

Collections

All Faculty Deposits
Scholarly Works, Biomedical Sciences and Pathobiology